

Remy Gressin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6792243/remy-gressin-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84
papers

4,371
citations

31
h-index

65
g-index

89
ext. papers

5,099
ext. citations

5.9
avg, IF

4.2
L-index

#	Paper	IF	Citations
84	CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL. <i>Cancers</i> , 2021 , 13,	6.6	3
83	Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1700-1709	4.4	1
82	Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP-treated DLBCL. <i>HemaSphere</i> , 2021 , 5, e598	0.3	1
81	Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1076-1084	4.4	8
80	Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. <i>Haematologica</i> , 2020 , 105, e33-e36	6.6	20
79	Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. <i>Neurology</i> , 2020 , 94, e1027-e1039	6.5	44
78	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. <i>Haematologica</i> , 2019 , 104, e562-e565	6.6	14
77	A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. <i>Haematologica</i> , 2019 , 104, 138-146	6.6	25
76	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 229-240	40	283
75	Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. <i>American Journal of Hematology</i> , 2018 , 93, 729-735	7.1	18
74	Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 629-635	4.9	10
73	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018 , 131, 174-181	2.2	78
72	BET Family Protein BRD4: An Emerging Actor in NFB Signaling in Inflammation and Cancer. <i>Biomedicines</i> , 2018 , 6,	4.8	75
71	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <i>Lancet Oncology, The</i> , 2018 , 19, 1449-1458	21.7	55
70	Consolidation anti-CD22 fractionated radioimmunotherapy with Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology,the</i> , 2017 , 4, e35-e45	14.6	23
69	Severe excessive daytime sleepiness induced by hydroxyurea. <i>Fundamental and Clinical Pharmacology</i> , 2017 , 31, 367-368	3.1	2
68	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1250-1260	59.2	205

67	Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. <i>Neuro-Oncology</i> , 2017 , 19, 422-429	1	17
66	Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. <i>Blood</i> , 2016 , 127, 3040-53	2.2	48
65	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016 , 18, 1297-303	1	80
64	Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1149-53	1.9	6
63	Treatment of the elderly patient with mantle cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 425-431	3.1	6
62	Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. <i>Lancet Haematology</i> , 2015 , 2, e251-9	14.6	115
61	Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. <i>Haematologica</i> , 2015 , 100, 1199-206	6.6	16
60	Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2986-8	1.9	12
59	Arsenic trioxide rewires mantle cell lymphoma response to bortezomib. <i>Cancer Medicine</i> , 2015 , 4, 1754-668	6	6
58	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014 , 93, 233-42	3	17
57	Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. <i>EMBO Molecular Medicine</i> , 2013 , 5, 1180-95	12	52
56	High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. <i>British Journal of Haematology</i> , 2013 , 162, 240-9	4.5	8
55	Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2013 , 2, 4	7.8	21
54	Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 104-10	2.2	115
53	The Ribvd Regimen (Rituximab IV, Bendamustine IV, Velcade SC, Dexamethasone IV) Offers a High Complete Response Rate In Elderly Patients With Untreated Mantle Cell Lymphoma. Preliminary Results Of The Lysa Trial Lymphome Du Manteau 2010 SA <i>Blood</i> , 2013 , 122, 370-370	2.2	4
52	Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia. <i>Annals of Oncology</i> , 2012 , 23, 2386-2390	10.3	9
51	Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang. <i>British Journal of Haematology</i> , 2012 , 158, 186-197	4.5	10
50	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. <i>Annals of Oncology</i> , 2012 , 23, 2187-2195	10.3	23

49	Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. <i>Annals of Oncology</i> , 2012 , 23, 1555-61	10.3	36
48	Accurate detection of the tumor clone in peripheral T-cell lymphoma biopsies by flow cytometric analysis of TCR-V β repertoire. <i>Modern Pathology</i> , 2012 , 25, 1246-57	9.8	14
47	Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. <i>Clinical Cancer Research</i> , 2012 , 18, 5203-11	12.9	170
46	A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. <i>Haematologica</i> , 2012 , 97, 1085-91	6.6	85
45	Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study. <i>Blood</i> , 2012 , 120, 152-152	2.2	9
44	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. <i>Blood</i> , 2012 , 120, 906-906 ²⁻²	2.2	3
43	Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. <i>Haematologica</i> , 2011 , 96, 1128-35	6.6	84
42	Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. <i>British Journal of Haematology</i> , 2010 , 151, 159-66	4.5	110
41	Multifocal polyclonal Epstein-Barr virus-associated B-cell lymphoproliferative disorder secondary to azathioprine therapy successfully treated with rituximab. <i>Leukemia and Lymphoma</i> , 2010 , 51, 174-7	1.9	2
40	Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 672-7	4.7	14
39	Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. <i>European Journal of Dermatology</i> , 2010 , 20, 16-23	0.8	44
38	Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. <i>Haematologica</i> , 2010 , 95, 1865-72	6.6	62
37	Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. <i>Blood</i> , 2010 , 115, 2420-9	2.2	52
36	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. <i>Haematologica</i> , 2010 , 95, 1350-7	6.6	34
35	Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 1633-42	8.8	66
34	1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma. <i>EMBO Molecular Medicine</i> , 2010 , 2, 159-71 ¹²	12	23
33	High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial. <i>Blood</i> , 2010 , 116, 1758-1758	2.2	2
32	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients. <i>Blood</i> , 2010 , 116, 2875-2875	2.2	3

31	No Benefit of First-Line Rituximab (R) - High-Dose Therapy (R-HDT) Over R-CHOP14 for Young Adults with Diffuse Large B-Cell Lymphoma. Preliminary Results of the GOELAMS 075 Prospective Multicentre Randomized Trial. <i>Blood</i> , 2010 , 116, 685-685	2.2	7
30	A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma.. <i>Blood</i> , 2010 , 116, 2803-2803	2.2	2
29	Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma. <i>Experimental Cell Research</i> , 2009 , 315, 3281-93	4.2	4
28	L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. <i>Annals of Oncology</i> , 2009 , 20, 110-6	10.3	90
27	Les lymphomes agressifs. <i>Medecine Nucleaire</i> , 2009 , 33, 478-481	0.1	2
26	High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. <i>Blood</i> , 2009 , 113, 995-1001	2.2	116
25	Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sjögren syndrome. <i>Scandinavian Journal of Infectious Diseases</i> , 2008 , 40, 343-6		14
24	Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1762-8	1.9	7
23	Composite splenic marginal zone lymphoma and mantle cell lymphoma arising from 2 independent B-cell clones. <i>Human Pathology</i> , 2007 , 38, 660-7	3.7	19
22	GMCLI, Goelams Mantle Cell Lymphoma Index, a New Prognostic Index of Survival for MCL Patients Treated with VAD-C and Autologous PBSCT.. <i>Blood</i> , 2006 , 108, 2447-2447	2.2	
21	High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. <i>Blood</i> , 2005 , 105, 3817-23	2.2	156
20	Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma. <i>Oncology</i> , 2005 , 69, 19-26	3.6	6
19	Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. <i>Annals of Oncology</i> , 2005 , 16, 466-72	10.3	17
18	Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. <i>New England Journal of Medicine</i> , 2004 , 350, 1287-95	59.2	287
17	In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. <i>Blood</i> , 2003 , 101, 949-54.	4.2	294
16	Transplantation in Waldenstrom's macroglobulinemia--the French experience. <i>Seminars in Oncology</i> , 2003 , 30, 291-6	5.5	58
15	Quality control for the validation of extracorporeal photopheresis process using the Vilbert-Lourmat UV-A irradiation's system. <i>Transfusion and Apheresis Science</i> , 2003 , 28, 63-70	2.4	23
14	Differentiation of anti-tumour cytotoxic T lymphocytes from autologous peripheral blood lymphocytes in non-Hodgkin's lymphomas. <i>British Journal of Haematology</i> , 2002 , 119, 425-31	4.5	10

13	Clinical and biologic features of CD4(+)CD56(+) malignancies. <i>Blood</i> , 2002 , 99, 1556-63	2.2	339
12	Identification of a leukemic counterpart of the plasmacytoid dendritic cells. <i>Blood</i> , 2001 , 97, 3210-7	2.2	312
11	Silicone lymphadenopathy mimicking a lymphoma in a patient with a metatarsophalangeal joint prosthesis. <i>Journal of Clinical Pathology</i> , 2000 , 53, 549-51	3.9	16
10	Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. <i>European Journal of Cancer</i> , 2000 , 36, 2360-7	7.5	20
9	Quantification of cellular adhesion molecules on malignant B cells from non-Hodgkin's lymphoma. <i>Leukemia</i> , 1999 , 13, 1428-33	10.7	17
8	Deletion 7q in B-cell low-grade lymphoid malignancies: a cytogenetic/fluorescence in situ hybridization and immunopathologic study. <i>Cancer Genetics and Cytogenetics</i> , 1999 , 109, 21-8		13
7	Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin's lymphomas. <i>Experimental Hematology</i> , 1999 , 27, 1185-93	3.1	14
6	Phenotypic, morphologic changes and Ig secretion induced on B-NHL cells in vitro by interferon alpha and all-trans-retinoic acid: possible progression toward a more differentiated state. <i>European Journal of Haematology</i> , 1998 , 61, 84-92	3.8	2
5	Portal vein thrombosis following splenectomy for hematologic disease: prospective study with Doppler color flow imaging. <i>World Journal of Surgery</i> , 1998 , 22, 1082-6	3.3	106
4	Growth modulation of freshly isolated non-Hodgkin's B-lymphoma cells induced by various cytokines and all-trans-retinoic-acid. <i>Leukemia and Lymphoma</i> , 1997 , 25, 169-78	1.9	8
3	. <i>Annals of Oncology</i> , 1997 , 8, 103-106	10.3	10
2	Autotumour reactive T-cell clones among tumour-infiltrating T lymphocytes in B-cell non-Hodgkin's lymphomas. <i>British Journal of Haematology</i> , 1995 , 90, 837-43	4.5	22
1	Non-Hodgkin's lymphomas with t(11;14)(q13;q32): a subset of mantle zone/intermediate lymphocytic lymphoma?. <i>British Journal of Haematology</i> , 1991 , 77, 346-53	4.5	134